JP2022504236A5 - - Google Patents
Info
- Publication number
- JP2022504236A5 JP2022504236A5 JP2021518561A JP2021518561A JP2022504236A5 JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5 JP 2021518561 A JP2021518561 A JP 2021518561A JP 2021518561 A JP2021518561 A JP 2021518561A JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5
- Authority
- JP
- Japan
- Prior art keywords
- indazole
- piperidine
- phenyl
- carboxamide
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740872P | 2018-10-03 | 2018-10-03 | |
| US62/740,872 | 2018-10-03 | ||
| PCT/US2019/054534 WO2020072797A1 (en) | 2018-10-03 | 2019-10-03 | Niraparib salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504236A JP2022504236A (ja) | 2022-01-13 |
| JP2022504236A5 true JP2022504236A5 (cg-RX-API-DMAC10.html) | 2022-11-04 |
| JP7472115B2 JP7472115B2 (ja) | 2024-04-22 |
Family
ID=68345029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518561A Active JP7472115B2 (ja) | 2018-10-03 | 2019-10-03 | ニラパリブ塩 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3860981B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7472115B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210071022A (cg-RX-API-DMAC10.html) |
| CN (2) | CN113166071B (cg-RX-API-DMAC10.html) |
| ES (1) | ES2967517T3 (cg-RX-API-DMAC10.html) |
| TW (2) | TWI853841B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020072797A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023524794A (ja) | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| JP2026517228A (ja) | 2023-05-17 | 2026-05-28 | テサロ， インコーポレイテッド | がんの治療におけるポリａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤の新規使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (cg-RX-API-DMAC10.html) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| MA50677A (fr) | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
-
2019
- 2019-10-03 CN CN201980078366.1A patent/CN113166071B/zh active Active
- 2019-10-03 EP EP19794786.4A patent/EP3860981B1/en active Active
- 2019-10-03 KR KR1020217012838A patent/KR20210071022A/ko active Pending
- 2019-10-03 TW TW108135909A patent/TWI853841B/zh active
- 2019-10-03 ES ES19794786T patent/ES2967517T3/es active Active
- 2019-10-03 CN CN202411070879.7A patent/CN118994103A/zh active Pending
- 2019-10-03 TW TW113130597A patent/TW202513550A/zh unknown
- 2019-10-03 JP JP2021518561A patent/JP7472115B2/ja active Active
- 2019-10-03 WO PCT/US2019/054534 patent/WO2020072797A1/en not_active Ceased